Usage of solid CYP1A2 inhibitors ought to be discontinued just before initiating pirfenidone and averted during therapy; if robust CYP1A2 inhibitors are the only real drug of selection, dosage reductions are advisable Disclosures: Muotri is a co-founder and has an equity interest in TISMOO, an organization focused on genetic analysis https://edwardx111kvf3.sharebyblog.com/profile